Krupi Parmar Selected Research

saroglitazar

7/2020	Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
1/2020	Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
1/2019	New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Krupi Parmar Research Topics

Disease

2	Type 2 Diabetes Mellitus (MODY) 07/2020 - 01/2020
2	Dyslipidemias (Dyslipidemia) 07/2020 - 01/2019
1	Hyperlipidemias (Hyperlipidemia) 07/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2019
1	Fatty Liver 01/2019

Drug/Important Bio-Agent (IBA)

3	saroglitazarIBA 07/2020 - 01/2019
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 07/2020 - 01/2019
2	LipidsIBA 01/2020 - 01/2019
1	Pioglitazone (Actos)FDA Link 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2019

Therapy/Procedure

1	Glycemic Control 01/2020